| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.91(B) |
| Last
Volume: |
21,280,549 |
Avg
Vol: |
11,944,728 |
| 52
Week Range: |
$44.7 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
69,103 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$4,525,215 |
$49,727,684 |
| Total People Sold |
0 |
0 |
3 |
6 |
| Total Sell Transactions |
0 |
0 |
3 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mily Elizabeth |
EVP, Strategy & BD |
• – – |
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,636 |
38,173 |
|
- |
|
| Judge Ann Powell |
EVP, Chief Human Resources |
• – – |
2023-02-06 |
4 |
S |
$74.69 |
$835,258 |
D/D |
(11,183) |
23,043 |
|
13% |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2023-02-06 |
4 |
S |
$74.65 |
$17,916,000 |
D/D |
(240,000) |
236,104 |
|
13% |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2023-02-01 |
4 |
D |
$71.23 |
$52,069 |
D/D |
(731) |
1,812 |
|
- |
|
| Meyers Gregory Scott |
EVP, Chief Digital & Tech Off. |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,543 |
2,543 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-12-02 |
4 |
D |
$81.13 |
$364,923 |
D/D |
(4,498) |
61,373 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
65,871 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2022-12-02 |
4 |
D |
$81.13 |
$109,444 |
D/D |
(1,349) |
43,254 |
|
- |
|
| Boerner Christopher S. |
EVP, Chief Commercial Officer |
• – – |
2022-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,637 |
44,603 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2022-12-02 |
4 |
D |
$81.13 |
$364,923 |
D/D |
(4,498) |
124,080 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2022-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
128,578 |
|
- |
|
| Judge Ann Powell |
EVP, Chief Human Resources |
• – – |
2022-11-09 |
4 |
S |
$80.45 |
$1,307,313 |
D/D |
(16,250) |
34,226 |
|
16% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-11-07 |
4 |
S |
$78.88 |
$3,621,381 |
D/D |
(45,910) |
57,079 |
|
15% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2022-11-07 |
4 |
OE |
$38.41 |
$3,067,529 |
D/D |
52,604 |
102,989 |
|
- |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2022-09-20 |
4 |
AS |
$69.71 |
$1,742,750 |
D/D |
(25,000) |
476,104 |
|
2% |
|
| Caforio Giovanni |
Board Chair and CEO |
• • – |
2022-09-15 |
4 |
S |
$71.84 |
$3,592,000 |
D/D |
(50,000) |
501,104 |
|
-1% |
|
| Judge Ann Powell |
EVP, Chief Human Resources |
• – – |
2022-09-14 |
4 |
S |
$70.75 |
$1,768,750 |
D/D |
(25,000) |
50,476 |
|
-4% |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2022-09-13 |
4 |
S |
$71.29 |
$9,551,167 |
D/D |
(133,951) |
119,786 |
|
-3% |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2022-09-13 |
4 |
OE |
$48.49 |
$5,977,702 |
D/D |
123,277 |
223,737 |
|
- |
|
| Weese Michelle |
EVP, Corporate Affairs |
• – – |
2022-07-01 |
4 |
D |
$76.84 |
$52,405 |
D/D |
(682) |
1,203 |
|
- |
|
| Weese Michelle |
EVP, Corporate Affairs |
• – – |
2022-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,885 |
1,885 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2022-07-01 |
4 |
D |
$76.84 |
$367,756 |
D/D |
(4,786) |
21,292 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2022-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,356 |
26,078 |
|
- |
|
| Leung Sandra |
EVP, General Counsel |
• – – |
2022-06-06 |
4 |
S |
$74.89 |
$4,867,850 |
D/D |
(65,000) |
308,627 |
|
6% |
|
| Haller Julia A |
Director |
– • – |
2022-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,949 |
13,619 |
|
- |
|
2225 Records found
|
|
Page 5 of 89 |
|
|
0.15 (0.34%) 
